S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

Homology Medicines Stock Forecast, Price & News

-0.71 (-5.27 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $12.77
50-Day Range
MA: $11.77
52-Week Range
Now: $12.77
Volume242,006 shs
Average Volume306,285 shs
Market Capitalization$578.02 million
P/E RatioN/A
Dividend YieldN/A
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Homology Medicines logo


Overall MarketRank

1.66 out of 5 stars

Medical Sector

253rd out of 1,926 stocks

Pharmaceutical Preparations Industry

127th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:FIXX



Sales & Book Value

Annual Sales$1.67 million
Book Value$5.73 per share


Net Income$-103,920,000.00
Net Margins-5,386.00%


Market Cap$578.02 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
-0.71 (-5.27 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for FIXX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

How has Homology Medicines' stock been impacted by Coronavirus (COVID-19)?

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, FIXX stock has decreased by 28.7% and is now trading at $12.77.
View which stocks have been most impacted by COVID-19

Is Homology Medicines a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Homology Medicines stock.
View analyst ratings for Homology Medicines
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Homology Medicines?

Wall Street analysts have given Homology Medicines a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Homology Medicines wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Homology Medicines' CEO?

1,448 employees have rated Homology Medicines CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Homology Medicines' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Homology Medicines

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) posted its earnings results on Monday, November, 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.81) by $0.19. The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.25 million. Homology Medicines had a negative net margin of 5,386.00% and a negative return on equity of 57.92%.
View Homology Medicines' earnings history

What price target have analysts set for FIXX?

7 brokers have issued twelve-month price objectives for Homology Medicines' stock. Their forecasts range from $27.00 to $34.00. On average, they anticipate Homology Medicines' share price to reach $30.43 in the next year. This suggests a possible upside of 138.3% from the stock's current price.
View analysts' price targets for Homology Medicines
or view Wall Street analyst' top-rated stocks.

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), (CGC) and Inovio Pharmaceuticals (INO).

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the following people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 57, Pay $845.78k)
  • Mr. W. Bradford Smith, CFO, Treasurer & Sec. (Age 64, Pay $552.76k)
  • Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 52, Pay $581.07k)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Mr. Timothy P. Kelly, Chief Technical Operations Officer (Age 51)
  • Dr. Paul Alloway J.D., Ph.D., Sr. VP & Gen. Counsel
  • Ms. Theresa McNeely, Chief Communications Officer & Patient Advocate (Age 56)
  • Ms. Melissa Gelormini, VP of HR
  • Dr. Gabriel M. Cohn M.B.A., M.D., Chief Medical Officer (Age 61)
  • Mr. Michael Blum M.B.A., Sr. VP of Commercial

When did Homology Medicines IPO?

(FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a number of retail and institutional investors. Top institutional investors include First Midwest Bank Trust Division (0.15%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Siyamak Rasty, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends for Homology Medicines

Which institutional investors are buying Homology Medicines stock?

FIXX stock was bought by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division.
View insider buying and selling activity for Homology Medicines
or or view top insider-buying stocks.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $12.77.

How big of a company is Homology Medicines?

Homology Medicines has a market capitalization of $578.02 million and generates $1.67 million in revenue each year. The company earns $-103,920,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Homology Medicines employs 206 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is www.homologymedicines.com.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.